Abstract
Neuropeptides are one of the most conserved proteins across different species and are ubiquitously expressed in different organs. In the peripheral nervous system, neuropeptides are secreted by the sensory and autonomic nerves and participate in a wide range of functions including immune surveillance, cardiovascular homeostasis, regulation of endocrine function, cytokine and growth factor release, and importantly angiogenesis. Neuropeptides including neuropeptide Y, substance P, calcitonin gene-related peptide, vasoactive intestinal peptide, and somatostatin (SS) are some of the neuropeptides that have been investigated regarding their role in modulating the vascular system and angiogenesis. All of these neuropeptides are pro-angiogenic except SS, which has anti-angiogenic properties. This chapter aims to present up-to-date evidence on the various mechanisms of action of the aforementioned neuropeptides and their clinical implications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hulagu S, Senturk O, Erdem A et al (2002) Effects of losartan, somatostatin and losartan plus somatostatin on portal hemodynamics and renal functions in cirrhosis. Hepatogastroenterology 49:783–787
Ruohonen ST, Abe K, Kero M et al (2009) Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury. Peptides 30:715–720
Kuo LE, Abe K, Zukowska Z (2007) Stress, NPY and vascular remodeling: implications for stress-related diseases. Peptides 28:435–440
Abe K, Tilan JU, Zukowska Z (2007) NPY and NPY receptors in vascular remodeling. Curr Top Med Chem 7:1704–1709
Zukowska Z, Grant DS, Lee EW (2003) Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med 13:86–92
Lee EW, Grant DS, Movafagh S et al (2003) Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 24:99–106
Ejaz A, LoGerfo FW, Pradhan L (2011) Diabetic neuropathy and heart failure: role of neuropeptides. Expert Rev Mol Med 13:e26
Jain M, LoGerfo FW, Guthrie P et al (2011) Effect of hyperglycemia and neuropeptides on interleukin-8 expression and angiogenesis in dermal microvascular endothelial cells. J Vasc Surg 53:1654–1660 e2
Pradhan L, Cai X, Wu S et al (2011) Gene expression of pro-inflammatory cytokines and neuropeptides in diabetic wound healing. J Surg Res 167:336–342
Zhang S, Liu Y, Guo S et al (2010) Vasoactive intestinal polypeptide relaxes isolated rat pulmonary artery rings through two distinct mechanisms. J Physiol Sci 60:389–397
Blomqvist AG, Herzog H (1997) Y-receptor subtypes—how many more? Trends Neurosci 20:294–298
Adrian TE, Allen JM, Bloom SR et al (1983) Neuropeptide Y distribution in human brain. Nature 306:584–586
Fried G, Terenius L, Hokfelt T et al (1985) Evidence for differential localization of noradrenaline and neuropeptide Y in neuronal storage vesicles isolated from rat vas deferens. J Neurosci 5:450–458
Ekblad E, Edvinsson L, Wahlestedt C et al (1984) Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 8:225–235
Zukowska Z, Pons J, Lee EW et al (2003) Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 81:89–94
Brothers SP, Wahlestedt C (2010) Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med 2:429–439
Franco-Cereceda A, Lundberg JM, Dahlof C (1985) Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol Scand 124:361–369
Erlinge D, Brunkwall J, Edvinsson L (1994) Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept 50:259–265
Zukowska-Grojec Z, Pruszczyk P, Colton C et al (1993) Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 14:263–268
Bedoui S, Kawamura N, Straub RH et al (2003) Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol 134:1–11
Pedrazzini T, Pralong F, Grouzmann E (2003) Neuropeptide Y: the universal soldier. Cell Mol Life Sci 60:350–377
Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W et al (1998) Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83:187–195
Kohno D, Gao HZ, Muroya S et al (2003) Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 52:948–956
Ejaz A, LoGerfo FW, Khabbaz K et al (2011) Expression of neuropeptide Y, substance P, and their receptors in the right atrium of diabetic patients. Clin Transl Sci 4:346–450
Robich MP, Matyal R, Chu LM et al (2010) Effects of neuropeptide Y on collateral development in a swine model of chronic myocardial ischemia. J Mol Cell Cardiol 49:1022–1030
Zatelli MC, Minoia M, Martini C et al (2010) Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 17:719–729
Lee EW, Michalkiewicz M, Kitlinska J et al (2003) Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 111:1853–1862
Movafagh S, Hobson JP, Spiegel S et al (2006) Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J 20:1924–1926
Ackermann PW, Ahmed M, Kreicbergs A (2002) Early nerve regeneration after Achilles tendon rupture—a prerequisite for healing? A study in the rat. J Orthop Res 20:849–856
Ekstrand AJ, Cao R, Bjorndahl M et al (2003) Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A 100:6033–6038
Lu C, Everhart L, Tilan J et al (2010) Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene 29:5630–5642
Lenkinski RE, Bloch BN, Liu F et al (2008) An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. MAGMA 21:411–421
Kitlinska J, Abe K, Kuo L et al (2005) Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 65:1719–1728
Hokfelt T, Kellerth JO, Nilsson G et al (1975) Experimental immunohistochemical studies on the localization and distribution of substance P in cat primary sensory neurons. Brain Res 100:235–252
Maggi CA (2000) The troubled story of tachykinins and neurokinins. Trends Pharmacol Sci 21:173–175
Pradhan L, Nabzdyk C, Andersen ND et al (2009) Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Rev Mol Med 11:e2
Maggi CA (1995) The mammalian tachykinin receptors. Gen Pharmacol 26:911–944
Nieber K, Oehme P (1982) [Substance P—a neuropeptide transmitter]. Z Gesamte Inn Med 37:577–582
Nilsson J, von Euler AM, Dalsgaard CJ (1985) Stimulation of connective tissue cell growth by substance P and substance K. Nature 315:61–63
Ziche M, Morbidelli L, Pacini M et al (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 40:264–278
Rameshwar P, Poddar A, Zhu G et al (1997) Receptor induction regulates the synergistic effects of substance P with IL-1 and platelet-derived growth factor on the proliferation of bone marrow fibroblasts. J Immunol 158:3417–3424
Khawaja AM, Rogers DF (1996) Tachykinins: receptor to effector. Int J Biochem Cell Biol 28:721–738
Harrison S, Geppetti P (2001) Substance p. Int J Biochem Cell Biol 33:555–576
Delgado AV, McManus AT, Chambers JP (2003) Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P. Neuropeptides 37:355–361
Chu JM, Chen LW, Chan YS et al (2011) Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway. Neuropharmacology 61:1389–1398
Bulut K, Felderbauer P, Deters S et al (2008) Sensory neuropeptides and epithelial cell restitution: the relevance of SP- and CGRP-stimulated mast cells. Int J Colorectal Dis 23:535–541
Felderbauer P, Bulut K, Hoeck K et al (2007) Substance P induces intestinal wound healing via fibroblasts—evidence for a TGF-beta-dependent effect. Int J Colorectal Dis 22:1475–1480
Couture R, Gaudreau P, St-Pierre S et al (1980) The dog common carotid artery: a sensitive bioassay for studying vasodilator effects of substance P and of kinins. Can J Physiol Pharmacol 58:1234–1244
Persson MG, Hedqvist P, Gustafsson LE (1991) Nerve-induced tachykinin-mediated vasodilation in skeletal muscle is dependent on nitric oxide formation. Eur J Pharmacol 205:295–301
Gustafsson LE, Wiklund CU, Wiklund NP et al (1990) Modulation of autonomic neuroeffector transmission by nitric oxide in guinea pig ileum. Biochem Biophys Res Commun 173:106–110
Amadesi S, Reni C, Katare R et al (2012) Role for substance P-based nociceptive signaling in progenitor cell activation and angiogenesis during ischemia in mice and in human subjects. Circulation 125(14):1774–1786
Andersson G, Backman LJ, Scott A et al (2011) Substance P accelerates hypercellularity and angiogenesis in tendon tissue and enhances paratendinitis in response to Achilles tendon overuse in a tendinopathy model. Br J Sports Med 45:1017–1022
Munoz M, Covenas R (2010) Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med 10:305–313
Munoz M, Rosso M, Covenas R (2011) The NK-1 receptor: a new target in cancer therapy. Curr Drug Targets 12:909–921
Wiedermann CJ, Auer B, Sitte B et al (1996) Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol 298:335–338
Kohara H, Tajima S, Yamamoto M et al (2010) Angiogenesis induced by controlled release of neuropeptide substance P. Biomaterials 31:8617–8625
Scott JR, Muangman P, Gibran NS (2007) Making sense of hypertrophic scar: a role for nerves. Wound Repair Regen 15(suppl 1):S27–S31
Burssens P, Steyaert A, Forsyth R et al (2005) Exogenously administered substance P and neutral endopeptidase inhibitors stimulate fibroblast proliferation, angiogenesis and collagen organization during Achilles tendon healing. Foot Ankle Int 26:832–839
Khare VK, Albino AP, Reed JA (1998) The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. J Cutan Pathol 25:2–10
Singh D, Joshi DD, Hameed M et al (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci U S A 97:388–393
Harford-Wright E, Lewis KM, Vink R (2011) Towards drug discovery for brain tumours: interaction of kinins and tumours at the blood brain barrier interface. Recent Pat CNS Drug Discov 6:31–40
Munoz M, Covenas R (2011) NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem 18:1820–1831
Munoz M, Rosso M, Robles-Frias MJ et al (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90:1259–1269
Mayordomo C, Garcia-Recio S, Ametller E et al (2012) Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J Cell Physiol 227:1358–1366
Adeghate E, Ponery A (2003) Pancreatic peptides, neuropeptides and neurotransmitters in diabetes mellitus: a review. Int J Diabetes Metab 11:1–6
Bergdahl A, Valdemarsson S, Nilsson T et al (1999) Dilatory responses to acetylcholine, calcitonin gene-related peptide and substance P in the congestive heart failure rat. Acta Physiol Scand 165:15–23
McLatchie LM, Fraser NJ, Main MJ et al (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333–339
van Rossum D, Hanisch UK, Quirion R (1997) Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 21:649–678
Walker CS, Conner AC, Poyner DR et al (2010) Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci 31:476–483
Brain SD, Williams TJ, Tippins JR et al (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313:54–56
Gardiner SM, Compton AM, Kemp PA et al (1991) Haemodynamic effects of human alpha-calcitonin gene-related peptide following administration of endothelin-1 or NG-nitro-L-arginine methyl ester in conscious rats. Br J Pharmacol 103:1256–1262
Manek S, Terenghi G, Shurey C et al (1993) Neovascularisation precedes neural changes in the rat groin skin flap following denervation: an immunohistochemical study. Br J Plast Surg 46:48–55
Manek S, Terenghi G, Shurey C et al (1994) Angiogenesis and reinnervation in skin flaps: the effects of ischaemia examined in an animal model. Int J Exp Pathol 75:243–255
Mapp PI, McWilliams DF, Turley MJ et al (2012) A role for the sensory neuropeptide calcitonin gene-related peptide in endothelial cell proliferation in vivo. Br J Pharmacol 166:1261–1271
Zheng S, Li W, Xu M et al (2010) Calcitonin gene-related peptide promotes angiogenesis via AMP-activated protein kinase. Am J Physiol Cell Physiol 299:C1485–C1492
Toda M, Suzuki T, Hosono K et al (2008) Roles of calcitonin gene-related peptide in facilitation of wound healing and angiogenesis. Biomed Pharmacother 62:352–359
Ohno T, Hattori Y, Komine R et al (2008) Roles of calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenterology 134:215–225
Toda M, Suzuki T, Hosono K et al (2008) Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide. Proc Natl Acad Sci U S A 105:13550–13555
White CM, Ji S, Cai H et al (2010) Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS Neurol Disord Drug Targets 9:661–666
Gaw AJ, Aberdeen J, Humphrey PP et al (1991) Relaxation of sheep cerebral arteries by vasoactive intestinal polypeptide and neurogenic stimulation: inhibition by L-NG-monomethyl arginine in endothelium-denuded vessels. Br J Pharmacol 102:567–572
Guan CX, Cui YR, Sun GY et al (2009) Role of CREB in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells. Regul Pept 153:64–69
Wollina U, Huschenbeck J, Knoll B et al (1997) Vasoactive intestinal peptide supports induced migration of human keratinocytes and their colonization of an artificial polyurethane matrix. Regul Pept 70:29–36
Wollina U, Knopf B (1993) Vasoactive-intestinal-peptide (vip) modulates early events of migration in human keratinocytes. Int J Oncol 2:229–232
Marion-Audibert AM, Nejjari M, Pourreyron C et al (2000) [Effects of endocrine peptides on proliferation, migration and differentiation of human endothelial cells]. Gastroenterol Clin Biol 24:644–648
Yang J, Zong CH, Zhao CH et al (2009) [Vasoactive intestinal peptide enhances angiogenesis after focal cerebral ischemia]. Nan Fang Yi Ke Da Xue Xue Bao 29:619–622
Yang J, Zong CH, Zhao ZH et al (2009) Vasoactive intestinal peptide in rats with focal cerebral ischemia enhances angiogenesis. Neuroscience 161:413–421
Zhao Z, Cheng Q, Li X et al (2006) [c-fos antisense oligodeoxynucleotide reduces VIP-induced upregulation of VEGF expression in small cell lung cancer cells]. Zhongguo Fei Ai Za Zhi 9:312–315
Collado B, Carmena MJ, Clemente C et al (2007) Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides 28:1896–1901
Collado B, Sanchez MG, Diaz-Laviada I et al (2005) Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochim Biophys Acta 1744:224–233
Ogasawara M, Murata J, Kamitani Y et al (1999) Inhibition by vasoactive intestinal polypeptide (VIP) of angiogenesis induced by murine colon 26-L5 carcinoma cells metastasized in liver. Clin Exp Metastasis 17:283–291
Brazeau P, Vale W, Burgus R et al (1974) Isolation of somatostatin (a somatotropin release inhibiting factor) of ovine hypothalamic origin. Can J Biochem 52:1067–1072
Ferjoux G, Bousquet C, Cordelier P et al (2000) Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 94:205–210
Dasgupta P (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102:61–85
Shulkes A (1994) Somatostatin: physiology and clinical applications. Baillieres Clin Endocrinol Metab 8:215–236
McIntosh CH, Bakich V, Kwok YN et al (1986) A comparison of the inhibitory effects of somatostatin-14, -25, and -28 on motility of the guinea pig ileum. Can J Physiol Pharmacol 64:303–306
Koch H (1976) [Gastrointestinal hormones and blood circulation in the gastric mucosa]. Z Gastroenterol 14(suppl):105–109
Tyden G, Samnegard H, Thulin L et al (1979) Circulatory effects of somatostatin in anesthetized man. Acta Chir Scand 145:443–446
Huang HC, Lee FY, Chan CC et al (2002) Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive rats. J Hepatol 36:163–168
Woltering EA, Barrie R, O’Dorisio TM et al (1991) Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50:245–251
Bocci G, Culler MD, Fioravanti A et al (2007) In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin Invest 37:700–708
Dal Monte M, Cammalleri M, Martini D et al (2007) Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest Ophthalmol Vis Sci 48:3480–3489
Laklai H, Laval S, Dumartin L et al (2009) Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci U S A 106:17769–17774
Hasskarl J, Kaufmann M, Schmid HA (2011) Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol 7:895–913
Zhou T, Xiao X, Xu B et al (2009) Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways. Acta Oncol 48:401–410
Faivre S, Sablin MP, Dreyer C et al (2010) Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol Metab Clin North Am 39:811–826
Valentino J, Evers BM (2011) Recent advances in the diagnosis and treatment of gastrointestinal carcinoids. Adv Surg 45:285–300
Florio T (2008) Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 13:822–840
Jia WD, Xu GL, Wang W et al (2009) A somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in mice. Tohoku J Exp Med 218:155–160
Zhao B, Yang P, Yang J et al (2011) A randomized trial of somatostatin to regulate the VEGFs/VEGFRs in patients with gastric cancer. Hepatogastroenterology 58:1425–1430
Sun LC, Luo J, Mackey LV et al (2007) A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett 246:157–166
Kumar M, Liu ZR, Thapa L et al (2004) Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts. Carcinogenesis 25:2075–2081
Hall GH, Turnbull LW, Bedford K et al (2005) Neuropilin-1 and VEGF correlate with somatostatin expression and microvessel density in ovarian tumours. Int J Oncol 27:1283–1288
Carrere N, Vernejoul F, Souque A et al (2005) Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther 16:1175–1193
Molina-Infante J, Perez-Gallardo B (2011) Somatostatin analogues for bleeding gastrointestinal angiodysplasias: when should thalidomide be prescribed? Dig Dis Sci 56:266–267
Fasciani A, Quilici P, Biscaldi E et al (2010) Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions. J Clin Endocrinol Metab 95:5315–5319
Prokosch V, Fink J, Heiduschka P et al (2011) VEGF, Ang-2 and SRIF associated abnormal postnatal development of the retinal capillary network in the Royal College of Surgeons rat. Exp Eye Res 92:128–137
Simo R, Carrasco E, Garcia-Ramirez M et al (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2:71–98
Palii SS, Afzal A, Shaw LC et al (2008) Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor. Invest Ophthalmol Vis Sci 49:5094–5102
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Pradhan-Nabzdyk, L., Nabzdyk, C. (2013). Neuropeptides and Angiogenesis. In: Mehta, J., Dhalla, N. (eds) Biochemical Basis and Therapeutic Implications of Angiogenesis. Advances in Biochemistry in Health and Disease, vol 6. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5857-9_4
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5857-9_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5856-2
Online ISBN: 978-1-4614-5857-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)